Previous 10 | Next 10 |
Gainers: SPI Energy Co. (NASDAQ: SPI ) +42% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +22% . DAVIDsTEA (NASDAQ: DTEA ) +17% . Dynagas LNG Partners LP (NYSE: DLNG ) +12% . Edesa Biotech (NASDAQ: EDSA ) +12% . SCYNEXIS (NASDAQ: SCYX ) +11% . Eyenovia (NASDAQ: EYEN ) +10% . elect...
Gainers: Aclaris Therapeutics (NASDAQ: ACRS ) +68% . Avadel Pharmaceuticals plc (NASDAQ: AVDL ) +20% . BioCardia ( OTCQB:BCDA ) +15% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +14% . Earthstone Energy (NYSE: ESTE ) +14% . Pier 1 Imports (NYSE: PIR ) +15% . SunPower Corporation (...
Aclaris Therapeutics (NASDAQ: ACRS ) +73% on positive A-101 data . More news on: Aclaris Therapeutics, Inc., Capricor Therapeutics, Inc., Ocean Power Technologies, Inc., Stocks on the move, Read more ...
Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) were up 18% at 3:39 p.m. EDT on Monday in anticipation of the biotech presenting data on its diabetes drug Zynquista at the European Association for the Study of Diabetes (EASD) annual meeting tomorrow. Zynquista is an SGLT inhibitor des...
LXRX stock is making a big move this week, with a gain of over 75% this week after Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ended a collaboration agreement with Sanofi (NASDAQ:SNY). Sanofi News Gives Boost The pharmaceutical sector has been one of the most dynamic sectors for investo...
Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) rose over 15% today and have gained about 90% in the last five days as investors continue to digest the fallout from a major partner walking away. On Sept. 10, the company and Sanofi terminated a collaboration to develop and commercia...
For a company that badly needed some good news, Lexicon Pharmaceuticals ' ( LXRX ) announcement of a settlement with now-former partner Sanofi ( SNY ) for its Zynquista SGLT-1/2 inhibitor is a welcome development. While the settlement, which returns full rights to the drug back to Lexicon a...
Gainers: Yuma Energy (NYSEMKT: YUMA ) +145% . T2 Biosystems (NASDAQ: TTOO ) +57% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +29% . Bicycle Therapeutics (NASDAQ: BCYC ) +25% . CARBO Ceramics (NYSE: CRR ) +23% . Luby's (NYSE: LUB ) +23% . CBL & Associates Properties (NYSE: CBL...
Yuma Energy (NYSEMKT: YUMA ) +69% announces third party purchase of senior secured bank debt. More news on: Yuma Energy, Inc., T2 Biosystems, Inc., Lexicon Pharmaceuticals, Inc., Stocks on the move, Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) has officially regained all rights to diabetes med Zynquista (sotagliflozin) after its collaboration agreement with Sanofi (NASDAQ: SNY ) expired yesterday. More news on: Lexicon Pharmaceuticals, Inc., Sanofi, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA ® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related ...
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced its participation in the Bank...
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentati...